Chris@CNW, Author at CannabisNewsWire

FridayJul 26, 2024 10:00 am

New Survey Shows Cannabis Could Reduce Prescription Analgesic Use

The state of Ohio legalized the medical use of cannabis in 2016, making it the 25th state in the country to do so. As of March 2024, the state had registered 167,153 patients who were legally allowed to use medical cannabis. Ohio’s medical cannabis program covers 26 eligible conditions, including post-traumatic stress disorder (“PTSD”) and chronic and intractable or severe pain, among others. The program permits cannabis to be sold as edibles, tinctures, oils, plant material and patches in 124 dispensaries across Ohio. Now, a recently conducted survey has discovered that the majority of medical marijuana patients have observed a…

ThursdayJul 25, 2024 4:20 pm

420 with CNW — Kentucky Governor Writes to DEA Admin Supporting Federal Marijuana Reform

Kentucky Governor Andy Beshear recently wrote to Anne Milgram, the U.S. Drug Enforcement Administration (DEA) administrator, to voice his backing of the Department of Health and Human Services’ proposal to relax cannabis restrictions. The proposal advocates for moving marijuana from Schedule 1 to Schedule 3 of the Controlled Substances Act (CSA). Governor Beshear highlighted that this reclassification would offer patients a safer alternative to harmful opioids, ensuring continued access to reliable products. He also noted that such a move would aid communities in reducing illegal drug use and crime. Additionally, it would level the economic playing field for marijuana businesses…

WednesdayJul 24, 2024 4:20 pm

420 with CNW — Marijuana Companies in Europe Consider Listing in US as Rescheduling Progresses

A number of European marijuana start-ups are thinking about listing in New York due to the anticipated reclassification of marijuana by federal authorities as a less harmful narcotic. Although the companies haven’t finalized their plans, they are drawn to the U.S. market’s increasingly favorable stance on cannabis and CBD products. Statista estimates that this year’s CBD market might be valued at approximately $6.90 billion. Under the new U.S. regulations, cannabis may be moved from the highly restrictive Schedule 1 of the Controlled Substances Act (CSA), which also includes LSD, heroin, and fentanyl, to the less restrictive Schedule 3, placing it…

WednesdayJul 24, 2024 10:00 am

State Cannabis Regulators Urge Feds to Provide Clarity Regarding Reclassification

The Cannabis Regulators Association (CANNRA) is requesting that the U.S. Drug Enforcement Administration and Biden Administration offer clarity on how rescheduling cannabis will affect enforcement by the federal government, particularly in legal states. In a public comment to the DEA’s administrator Anne Milgram, CANNRA leaders explained that without federal guidance, territorial and state government agencies would be left guessing and hypothesizing about these dynamics and their possible effects on legal programs regulated by states, and the populations impacted by these programs in various jurisdictions, among other things. CANNRA is an organization that represents hemp and cannabis regulators in more than…

WednesdayJul 24, 2024 9:00 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a high unmet medical need Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality of life, making it…

TuesdayJul 23, 2024 4:20 pm

420 with CNW — Curaleaf, Other MSOs Switching to Hemp-Sourced THC

Curaleaf Holdings had decided to step away from hemp. The New York-based cannabis multistate operator initially ran a hemp farm in Lexington, Kentucky, for its CBD product line starting in 2018. According to its annual filings, Curaleaf terminated its lease, stopped all hemp-related manufacturing and wholesale operations in Kentucky by the end of September last year and listed its assets for sale. However, Curaleaf recently reentered the hemp business, following a larger cannabis industry trend for licensed businesses. The company introduced a new range of THC-derived hemp products on June 24, 2024, under The Hemp Co. brand. The hemp-based, shelf-stable…

MondayJul 22, 2024 4:20 pm

420 with CNW — Recent Supreme Court Decision Could Impact Marijuana Reclassification

The recent decision by the U.S. Supreme Court to limit the power of federal regulatory agencies has introduced new uncertainty regarding the future of cannabis rescheduling. However, administrative law and policy experts believe that the ambiguity is not expected to hinder the Biden administration’s reclassification process. In a 6-to-3 decision last Friday, the court ruled that courts are no longer obligated to follow federal agencies’ interpretations of statutes when Congress leaves those interpretations unclear. This ruling effectively ends the Chevron doctrine, named after a 1984 judgment. Historically, courts would defer to regulators as the subject matter experts. There is speculation…

MondayJul 22, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) to Validate Earlier Semaglutide Studies with Successful GLP-1-H24-2 Study Dosing

Lexaria, a global innovator in drug delivery platforms, recently completed dosing of its human pilot study #2, GLP-1-H24-2 The study is to explore the tolerability, side effects, and blood levels of semaglutide, a glucagon-like peptide-1 (“GLP-1”) drug For Lexaria, the results from this study look to validate earlier studies that have demonstrated improvements in the delivery of semaglutide into the bloodstream Results from the GLP-1-H24-2 study are set to be announced in late August or early September Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced the dosing completion of its human pilot study #2, GLP-1-H24-2.…

MondayJul 22, 2024 10:00 am

Did Congress Inadvertently Legalize Marijuana in 2018?

Congress federally legalized hemp when it approved the 2018 Farm Bill, making the use of hemp as well as its production legal. Legislators who supported the legalization of this industrial crop expected that it would be used for textiles and nonintoxicating supplements such as shelled hemp seeds and CBD oil. What they didn’t realize, however, was that with some tweaking, hemp could also induce highs when consumed. Currently, individuals in different parts of the country can get high on THC derived from hemp without breaking the law. These hemp-based intoxicants are every bit as strong as compounds derived from cannabis…

FridayJul 19, 2024 4:20 pm

420 with CNW — Study Links Marijuana Use to Improved Quality, Frequency of Sex

A recent scientific assessment of scholarly studies on human sexuality and cannabis has found that there is a complex link between sex and cannabis use. However, the general consensus is that cannabis tends to increase the frequency, enjoyment and desire for sex. The review, published in the “Psychopharmacology Journal,” suggests that higher amounts of cannabis may impair performance and desire, while smaller doses may be more favorable to sexual fulfillment. The effects also appear to vary based on gender. The study’s authors noted that marijuana can improve intimacy with partners, reduce shame and anxiety, lessen inhibitions and increase sexual pleasure.…